Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

A new warhead in lymphoma therapy?

Andrew McMillan

Blood (2021) 137 (19): 2568–2570.

https://doi.org/10.1182/blood.2020009782

Published: 2021

Journal Articles

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew Davies, Josh Caddy, Katy Mercer, Geoff N Saunders, Louise Stanton, Graham P. Collins, MD DPhil, Thomas E C Cummin, MRCP MBBCh BSc, Anna Schuh, MD MRCP, PhD, Kirit M. Ardeshna, Andrew McMillan, John A. Radford, MD FMedSci, David John Lewis, MD, Adam Coleman, Gareth Griffiths, Cathy Burton, MBBChir, MA, MD FRCPath, Sharon Barrans, Peter Johnson, MD FRCP

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134546

Published: 2020

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Laurie H. Sehn, MDMPH, Mark Hertzberg, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Alex F. Herrera, MD, Sarit E Assouline, MD MSc, Christopher Flowers, MDMS, Tae Min Kim, MD PhD, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, MD PhD, Lisa Musick, Jamie Hirata, YiMeng Chang, Grace Ku, Matthew J Matasar, MD

Blood (2020) 136 (Supplement 1): 17–19.

https://doi.org/10.1182/blood-2020-137078

Published: 2020

Journal Articles

Impact of Intended and Relative Dose Intensity of RCHOP in a Large, Consecutive Cohort of Elderly DLBCL Patients: No Difference in DFS for 70-80 Years Versus >80 Years and Idi Independently Predicts Survival

Toby A. Eyre, Nicolas Martinez-Calle, MD, Catherine Hildyard, David W. Eyre, Hannah Plaschkes, Jonathan Griffith, Julia Wolf, Chris P Fox, Andrew McMillan, Mark Bishton, Graham P. Collins, MB BS DPhil, Chris Hatton, MD

Blood (2018) 132 (Supplement 1): 573.

https://doi.org/10.1182/blood-2018-99-110330

Published: 2018

Journal Articles

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Laurie H Sehn, MDMPH, Alex F. Herrera, MD, Matthew J Matasar, Manali Kamdar, Sarit Assouline, Mark Hertzberg, Tae Min Kim, Won-Seog Kim, Andrew McMillan, Muhit Özcan, Jamie M Hirata, Elicia Penuel, Ji Cheng, Grace Ku, Christopher R Flowers, MDMS

Blood (2018) 132 (Supplement 1): 1683.

https://doi.org/10.1182/blood-2018-99-118551

Published: 2018

Journal Articles

CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement

Toby A. Eyre, Nicolas Martinez-Calle, MD #, Amy A Kirkwood, MSc, Catherine Hildyard, Murali Kesavan, Joseph Butler, Carolyn Mercer, Faouzi Djebbari, Hannah Plaschkes, John Griffith, Stephen Booth, Andrew McMillan, Mark Bishton, Christopher P. Fox, MD PhD, Graham P. Collins, MB BS DPhil, Chris Hatton

Blood (2018) 132 (Supplement 1): 1694.

https://doi.org/10.1182/blood-2018-99-111010

Published: 2018

Journal Articles

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Mary Gleeson, Nicholas Counsell, David Cunningham, Eliza Hawkes, Anthony Lawrie, Andrew Jack, Paul Smith, Christopher Pocock, MD PhD, Kirit M. Ardeshna, MB BChir, John Radford, MD FRCP, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, MD, David C. Linch

Blood (2018) 132 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2018-99-111824

Published: 2018

Journal Articles

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Blood (2016) 128 (22): 1746.

https://doi.org/10.1182/blood.V128.22.1746.1746

Published: 2016

Journal Articles

Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

Elizabeth H Phillips, Amy A Kirkwood, Anthony Lawrie, Simon Rule, Russell Patmore, MRCP FRCPath, Ruth Pettengell, Cathy H Burton, Kirit M Ardeshna, Silvia Montoto, MD, Shankaranarayana Paneesha, Paul Smith, Katharina Wanek, Laura Clifton-Hadley, PhD BSc, David C. Linch, MD MRCP, MB BCh, BA, Andrew McMillan, PhD

Blood (2016) 128 (22): 1855.

https://doi.org/10.1182/blood.V128.22.1855.1855

Published: 2016

Journal Articles

Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma

Andrew McMillan, PhD, Alejandro Martín, MD PhD, Corinne Haioun, MD PhD, Annalisa Chiappella, Alice Di Rocco, MD PhD, Antonio Rueda, Christina Palaska, Andrew J Davies, FRCP PhD

Blood (2016) 128 (22): 4204.

https://doi.org/10.1182/blood.V128.22.4204.4204

Published: 2016

Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP

Blood (2015) 126 (23): 812.

https://doi.org/10.1182/blood.V126.23.812.812

Published: 2015

Journal Articles

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Dina Okasha, Amy A Kirkwood, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Emma Lawrie, Andrew McMillan, PhD, Tobias F. Menne, MD PhD FRCPath, Nick Morley, Clare Rowntree, Deborah Susan Richardson, MDFRCPath,FRCP,MA,MBBChir, Paul Smith, Adele K. Fielding, MB BS, PhD, David Marks, MD PhD

Blood (2015) 126 (23): 733.

https://doi.org/10.1182/blood.V126.23.733.733

Published: 2015

Journal Articles

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Blood (2015) 126 (23): 1516.

https://doi.org/10.1182/blood.V126.23.1516.1516

Published: 2015

Journal Articles

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Barrans Sharon, PhD, Andrew J Davies, MRCP, Ming Wang, Ming-Qing Du, MB, PhD, Christoph Mamot, MD, Keith Pugh, PhD, Josh Caddy, Matthew A Care, PhD, Jan Taylor, Reuben M Tooze, PhD FRCP, Tom Maishman, Louise Stanton, PhD, Debbie Hamid, Andrew McMillan, PhD, Paul Fields, MD PhD, Andrew Jack, PhD MB, Peter Johnson, MD

Blood (2015) 126 (23): 331.

https://doi.org/10.1182/blood.V126.23.331.331

Published: 2015

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Mary Gleeson, FRCPath, David Cunningham, FMedSci, Eliza A Hawkes, MD, Wendi Qian, PhD, Paul Smith, MSc, Nick Chadwick, Paul Mouncey, MSc, Andrew Jack, PhD, Christopher Pocock, MD PhD, Kirit M Ardeshna, MD FRCPath, John Radford, Andrew McMillan, PhD, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter W.M. Johnson, FRCP, Joanna Gambell, BSc, David C Linch, FMedSci

Blood (2014) 124 (21): 1723.

https://doi.org/10.1182/blood.V124.21.1723.1723

Published: 2014

Journal Articles

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

Nahid Zareian, Bella Patel, MBBS, FRCPath, Lena Rai-Shetty, PhD, Clare Rowntree, PhD, Andrew McMillan, FRCP, FRCPath, PhD, David I Marks, Tobias Menne, Paul Smith, Simon Purnell, Lynda Micklewright, Anthony V. Moorman, Adele Fielding, MB BS, PhD

Blood (2013) 122 (21): 1335.

https://doi.org/10.1182/blood.V122.21.1335.1335

Published: 2013

Journal Articles

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Bella Patel, MB, BS, MD, A Kirkwood, Aditi Dey, Clare Rowntree, Andrew McMillan, FRCP, FRCPath, PhD, David Marks, MD, PhD, Tobias Menne, Paul Smith, PhD, Simon Purnell, Lynda Micklewright, Adele K Fielding, MB, BS, PhD

Blood (2013) 122 (21): 3900.

https://doi.org/10.1182/blood.V122.21.3900.3900

Published: 2013

Journal Articles

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Andrew McMillan, FRCP, FRCPath, PhD, Kirit M Ardeshna, FRCPath, Jo Gambell, Andrew Jack, PhD, Amy Kirkwood, Anthony Laurie, Silvia Montoto, MD, Shankaranarayana Paneesha, MD, Simon Rule, MD, Russell Patmore, MD, Ruth Pettengell, Humra Shah, Paul Smith, David Linch, FMedSci

Blood (2013) 122 (21): 4348.

https://doi.org/10.1182/blood.V122.21.4348.4348

Published: 2013

NARROW

A new warhead in lymphoma therapy?

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Impact of Intended and Relative Dose Intensity of RCHOP in a Large, Consecutive Cohort of Elderly DLBCL Patients: No Difference in DFS for 70-80 Years Versus >80 Years and Idi Independently Predicts Survival

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only